Case studies of lead candidates such as mRNA-based enzyme replacement for PA, VEGF-A mRNA for post-cardiac surgery angiogenesis, and CFTR gene delivery for cystic fibrosis demonstrate proof-of-concept efficacy and safety in early-stage trials, offering hope for patients with limited therapeutic options. The gene discussed is CFTR; the disease is cystic fibrosis.